FDA Regulatory Pathways for Biotech Researchers Working Outside Large Institutions

The FDA's regulatory pathway for drugs, devices, and diagnostics is designed for large institutional actors. Here's how independent biotech researchers navigate it.

Assemble Teams Compliance Team ·June 28, 2026 ·1 min read

12+

years average time from drug discovery to FDA approval — and independent researchers who don't understand the regulatory pathway early waste years on work that doesn't survive the review process.

The FDA's regulatory framework for drugs, biologics, and medical devices is among the most complex compliance landscapes in any technical field. It was designed around large institutional actors — pharmaceutical companies with dedicated regulatory affairs departments, medical device manufacturers with quality management systems — not independent researchers or small startups working on mission-based programs.

Understanding the basics of FDA pathways before your first biotech mission isn't about becoming a regulatory expert. It's about knowing which decisions made in the research phase will determine what pathway your product can take — and which will close pathways permanently.

Drug development pathways

New drugs follow the Investigational New Drug (IND) application pathway. Before any clinical testing in humans, you must file an IND with the FDA. The IND includes your pre-clinical testing data, your proposed clinical protocol, information about the drug's chemistry, manufacturing, and controls (CMC), and an investigator brochure. The FDA has 30 days to place a clinical hold if it has safety concerns; otherwise, clinical testing can begin.

For independent researchers working on drug discovery, the IND stage typically requires institutional partnership — a university or hospital with an IRB (Institutional Review Board) and the infrastructure to sponsor human trials. This partnership needs to be built into the mission structure from day one, not discovered as a requirement when the research is ready for clinical translation.

Medical device pathways

Medical devices are classified as Class I (low risk, general controls), Class II (moderate risk, special controls and premarket notification via the 510(k) pathway), or Class III (high risk, premarket approval via the PMA pathway). Most devices developed by independent engineers and researchers fall into Class II — requiring either a 510(k) clearance demonstrating substantial equivalence to a predicate device, or a De Novo classification for novel low-to-moderate risk devices.

The 510(k) process takes 3–6 months for straightforward submissions; the PMA process for Class III devices takes 1–3 years with a full clinical trial requirement. Getting your device classification right — and understanding which category your development work falls into — determines the entire regulatory timeline for the project.